RegentAtlantic Capital’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $21.2M | Sell |
41,755
-458
| -1% | -$256K | 0.63% | 23 |
|
|
2022
Q2 | $22.9M | Sell |
42,213
-486
| -1% | -$268K | 0.76% | 20 |
|
|
2022
Q1 | $25.2M | Sell |
42,699
-561
| -1% | -$322K | 0.71% | 23 |
|
|
2021
Q4 | $28.9M | Buy |
43,260
+63
| +0.1% | +$39.3K | 0.81% | 20 |
|
|
2021
Q3 | $24.7M | Sell |
43,197
-431
| -1% | -$237K | 0.75% | 19 |
|
|
2021
Q2 | $22M | Sell |
43,628
-514
| -1% | -$243K | 0.68% | 23 |
|
|
2021
Q1 | $20.1M | Buy |
44,142
+870
| +2% | +$415K | 0.68% | 20 |
|
|
2020
Q4 | $20.2M | Sell |
43,272
-582
| -1% | -$273K | 0.8% | 22 |
|
|
2020
Q3 | $19.4M | Buy |
43,854
+1,863
| +4% | +$770K | 0.87% | 21 |
|
|
2020
Q2 | $15.2M | Sell |
41,991
-1,402
| -3% | -$470K | 0.85% | 21 |
|
|
2020
Q1 | $12.3M | Sell |
43,393
-3,264
| -7% | -$1.03M | 0.96% | 24 |
|
|
2019
Q4 | $15.2M | Sell |
46,657
-1,843
| -4% | -$559K | 0.92% | 25 |
|
|
2019
Q3 | $14.1M | Sell |
48,500
-1,717
| -3% | -$492K | 0.93% | 22 |
|
|
2019
Q2 | $14.7M | Sell |
50,217
-1,186
| -2% | -$327K | 0.99% | 19 |
|
|
2019
Q1 | $14.1M | Sell |
51,403
-2,871
| -5% | -$714K | 0.98% | 19 |
|
|
2018
Q4 | $12.1M | Sell |
54,274
-1,171
| -2% | -$275K | 1.03% | 19 |
|
|
2018
Q3 | $13.5M | Sell |
55,445
-1,082
| -2% | -$249K | 1.04% | 20 |
|
|
2018
Q2 | $11.7M | Sell |
56,527
-761
| -1% | -$162K | 1.01% | 24 |
|
|
2018
Q1 | $11.8M | Sell |
57,288
-1,140
| -2% | -$239K | 0.99% | 23 |
|
|
2017
Q4 | $11.1M | Sell |
58,428
-2,048
| -3% | -$392K | 0.91% | 31 |
|
|
2017
Q3 | $11.4M | Sell |
60,476
-754
| -1% | -$137K | 0.99% | 24 |
|
|
2017
Q2 | $10.7M | Sell |
61,230
-1,595
| -3% | -$268K | 0.97% | 28 |
|
|
2017
Q1 | $9.65M | Sell |
62,825
-1,497
| -2% | -$229K | 0.9% | 33 |
|
|
2016
Q4 | $9.08M | Sell |
64,322
-2,779
| -4% | -$410K | 0.89% | 32 |
|
|
2016
Q3 | $10.7M | Sell |
67,101
-3,859
| -5% | -$595K | 1.1% | 21 |
|
|
2016
Q2 | $10.5M | Sell |
70,960
-4,837
| -6% | -$714K | 1.01% | 20 |
|
|
2016
Q1 | $10.7M | Sell |
75,797
-3,312
| -4% | -$444K | 1.18% | 15 |
|
|
2015
Q4 | $11.2M | Sell |
79,109
-1,327
| -2% | -$177K | 1.2% | 20 |
|
|
2015
Q3 | $9.84M | Sell |
80,436
-1,940
| -2% | -$253K | 0.95% | 26 |
|
|
2015
Q2 | $10.7M | Sell |
82,376
-2,750
| -3% | -$359K | 0.95% | 25 |
|
|
2015
Q1 | $11.4M | Sell |
85,126
-1,424
| -2% | -$184K | 1% | 23 |
|
|
2014
Q4 | $10.8M | Sell |
86,550
-660
| -0.8% | -$80.3K | 0.92% | 24 |
|
|
2014
Q3 | $10.6M | Sell |
87,210
-1,090
| -1% | -$133K | 0.99% | 22 |
|
|
2014
Q2 | $10.4M | Sell |
88,300
-1,867
| -2% | -$220K | 0.97% | 22 |
|
|
2014
Q1 | $10.8M | Sell |
90,167
-3,688
| -4% | -$438K | 1.06% | 20 |
|
|
2013
Q4 | $10.5M | Sell |
93,855
-1,193
| -1% | -$119K | 1.01% | 19 |
|
|
2013
Q3 | $8.76M | Sell |
95,048
-2,469
| -3% | -$223K | 0.96% | 21 |
|
|
2013
Q2 | $8.25M | Buy |
+97,517
| New | +$8.12M | 0.98% | 21 |
|
Other funds holding TMO
RegentAtlantic Capital's TMO Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Thermo Fisher Scientific (TMO) stake by 1.1% in Q3 2022, selling an estimated $256K and leaving 41,755 shares worth $21.2M. The position accounts for 0.63% of the portfolio, ranked #23.
RegentAtlantic Capital first reported a position in TMO in Q2 2013 and has held it in 38 quarters since. The position peaked at $28.9M in Q4 2021. 2,266 funds tracked by Wall St. Rank hold TMO as of Q3 2022.
- RegentAtlantic Capital held 41,755 shares of Thermo Fisher Scientific worth $21.2M as of Q3 2022.
- RegentAtlantic Capital sold 458 Thermo Fisher Scientific shares in Q3 2022, an estimated $256K.
- Thermo Fisher Scientific made up 0.63% of RegentAtlantic Capital's portfolio in Q3 2022, its #23 holding.
- RegentAtlantic Capital first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Thermo Fisher Scientific position peaked at $28.9M in Q4 2021.
- 2,266 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.